Dr. Lonial Discusses Recent Updates in Multiple Myeloma

Video

In Partnership With:

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses updates in multiple myeloma.

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses updates in multiple myeloma.

Recently, highly active induction regimens that combine proteasome inhibitors and IMiDS with transplant and risk adapted maintenance have been shown to put most patients into remission for 3 to 5 years. This contrasts with the past 15 years of treatment that, according to Lonial, lacked effective drugs in the induction therapy setting.

Immune-based agents such elotuzumab (Empliciti) and daratumumab (Darzalex) are also in the mix, as well as other small molecules in development, says Lonial.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD